Mark Vignola | Intercept Pharmaceuticals, Inc. |
Mark Pruzanski | Intercept Pharmaceuticals, Inc. |
Richard Kim | Intercept Pharmaceuticals, Inc. |
Lisa Bright | Intercept Pharmaceuticals, Inc. |
Sandip S. Kapadia | Intercept Pharmaceuticals, Inc. |
Salveen Richter | Goldman Sachs & Co. LLC |
Michael J. Yee | Jefferies LLC |
Brian Abrahams | RBC Capital Markets LLC |
Alethia Young | Cantor Fitzgerald |
Joseph P. Schwartz | Leerink Partners LLC |
Brian P. Skorney | Robert W. Baird & Co., Inc. |
Jay Olson | Oppenheimer & Co., Inc. |
Yasmeen Rahimi | ROTH Capital Partners LLC |
Irina Margine | Cowen and Co. LLC |
Steven Seedhouse | Raymond James & Associates, Inc. |
Aspen Mori | Merrill Lynch, Pierce, Fenner & Smith, Inc. |
Joseph Stringer | Needham & Co. LLC |
Joel L. Beatty | Citigroup Global Markets, Inc. |
Yanan Zhu | Wells Fargo Securities LLC |
Francois Brisebois | Laidlaw & Co. (UK) Ltd. (United States) |
Thank you for joining the Intercept Pharmaceuticals Third Quarter 2018 Financial Results Conference Call. All participants are now in a listen-only mode.
Following the opening remarks, Intercept's management will open the lines for a question-and-answer period. Please be advised that this call is being recorded at the company's request and the webcast of this call will be archived on the company's website for approximately two weeks. I would now like to introduce Dr.